2252403-82-8 Usage
General Description
The chemical "7-chloro-6-fluoro-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione" is a complex heterocyclic compound with a pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione core. It contains chlorine and fluorine substituents at the 7 and 6 positions, respectively, and a methyl and isopropyl group attached to the 4-methyl-2-(propan-2-yl)pyridin-3-yl moiety. This chemical structure suggests potential pharmacological activity, as pyrido[2,3-d]pyrimidine derivatives have been investigated for their anti-cancer, anti-inflammatory, and anti-microbial properties. Further research and investigation are necessary to determine the specific biological and chemical properties of this compound.
Check Digit Verification of cas no
The CAS Registry Mumber 2252403-82-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,2,5,2,4,0 and 3 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 2252403-82:
(9*2)+(8*2)+(7*5)+(6*2)+(5*4)+(4*0)+(3*3)+(2*8)+(1*2)=128
128 % 10 = 8
So 2252403-82-8 is a valid CAS Registry Number.
2252403-82-8Relevant articles and documents
Improved Synthesis of New FDA-Approved Treatment for KRAS G12C Mutation in Non-small Cell Lung Cancer
Kargbo, Robert B.
, p. 1186 - 1187 (2021)
-
Pyridopyrimidinone compound and application thereof
-
, (2021/01/24)
The invention provides a pyridopyrimidinone compound with a structure as shown in a general formula (II) and application thereof. Researches prove that the compound provided by the invention can effectively inhibit KRAS G12C mutation. KRAS mutation accounts for a large proportion in tumors, no approved drug is obtained for treatment at present, and the compound provided by the invention has the potential to become a therapeutic drug for malignant tumors (especially non-small cell lung cancer (NSCLC) and colorectal cancer) carrying KRAS G12C mutation, and has a great application value.
IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND
-
, (2021/05/21)
The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
